Resources for your practice

IF YOU HAVE QUESTIONS ABOUT NUEDEXTA OR NEED REIMBURSEMENT SUPPORT

CALL 1-855-4NUEDEX (468-3339)
or visit
www.AdvancedPatientServices.com

Document your diagnosis of pseudobulbar affect using ICD-10 code F48.2a,22

PBA Screening Questionnaire

Center for Neurologic Study-Lability Scale (CNS-LS) for measuring pseudobulbar effect (PBA) symptoms


Download the
Questionnaire

Pivotal Trial Publication

Data from the pivotal safety and efficacy trial for NUEDEXTA are presented in this article from Annals of Neurology.

Download the full Pivotal Trial Publication

 

An alternative dosage strength used in this study, dextromethorphan/quinidine 30 mg/10 mg, is not approved by the FDA.

NUEDEXTA Patient Brochure

Share this informational brochure with your patients to learn about NUEDEXTA—the first-and-only
FDA-approved treatment for PBA.

Download the
NUEDEXTA Patient
Brochure

aICD-10-CM codes submitted to the payer must be determined by the provider/physician and accurately describe the diagnosis for which the patient receives NUEDEXTA treatment, represent codes at the highest level of specificity and reflect the contents of any clinical notes and/or chart documentation. The coding information contained herein is gathered from various resources and is subject to change. Nothing in this document is intended to serve as reimbursement advice, a guarantee of coverage, or a guarantee of payment for NUEDEXTA. Please refer to your payer plans for specific guidance.